CD300a/LMIR1 Fc Chimera Protein, Human,specification,price,image-Bio-Equip in China

Product Detail
Company Profile

Product Specification

Species	Human
Synonyms	CLM-8, CMRF-35-H9, CMRF35-H9, CMRF35-H, IRC1, IRC2, IgSF12, IRp60, CMRF35H, IGSF12
Accession	Q9UGN4-1
Amino Acid Sequence	Leu18-Gln178, with C-terminal hIgG1 Fc
Expression System	HEK293
Molecular Weight	45-55kDa (Reducing)
Purity	＞95% by SDS-PAGE
Endotoxin	<0.1EU/μg
Conjugation	Unconjugated
Physical Appearance	Lyophilized Powder
Storage Buffer	PBS, pH7.4.
Reconstitution	Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage	· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles.
Reference	1. Ze Tang, Hongfei Cai, Rui Wang, and Youbin Cui. Overexpression of CD300A inhibits progression of NSCLC through downregulating Wnt/β-catenin pathway. Onco Targets Ther. 2018 Dec 7:11:8875-8883. eCollection 2018.

Background

CD300A, also known as IRp60, is a type I transmembrane glycoprotein receptor of the CD300 glycoprotein family. It is located on the surface of cell membranes.CD300A is differentially expressed on the surface of various blood cells, including T lymphocytes, B lymphocytes, natural killer (NK) cells, neutrophils, and monocytes, and is involved in the regulation of cell growth, proliferation, apoptosis, differentiation, and immune regulation. Increasing evidences show that CD300A also plays a role in the development of hematological malignancies. Jiang et al revealed that knockdown of CD300A by shRNA interference could inhibit cell growth and division in diffuse large B-cell lymphoma (DLBCL) cells, but has no effect on cell apoptosis.In acute myeloid leukemia (AML), knockdown of CD300A also decreases cell proliferation and migration and induces cell apoptosis. However, whether CD300A plays a role in the progression of solid tumors remains unclear.